Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

Oncology

Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients With Cancer
Condition:   Malignant Solid Neoplasm
Intervention:   Other: Internet-Based Intervention
Sponsor:   Ohio State University Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
Condition:   Lymphoma, Large B-Cell, Diffuse
Intervention:   Behavioral: Digital Health Coaching
Sponsors:   Pack Health;   Novartis;   Ohio State University Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Conditions:   Amyloidosis;   AL Amyloidosis
Intervention:   Drug: ZN-d5
Sponsor:   K-Group Alpha, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Condition:   Solid Tumor
Intervention:   Drug: 23ME-00610
Sponsor:   23andMe, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Conditions:   Ovarian Cancer;   Ovarian Carcinoma;   Ovary Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: STRO-002;   Drug: Bevacizumab
Sponsor:   Sutro Biopharma, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 21, 2022 / by / in
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Conditions:   Gynecologic Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Non-small Cell Lung Cancer;   Cholangiocarcinoma;   Ovarian Cancer;   Endometrial Cancer;   Ovarian Carcinoma;   Ovary Neoplasm;   Squamous Cell Lung Cancer;   Adenocarcinoma of Lung;   Adenosquamous Cell Lung Cancer
Intervention:   Biological: Neoantigen specific TCR-T cell drug product
Sponsor:   Ziopharm
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Walnuts and Colon Health
Conditions:   Colorectal Cancer;   Diet Habit
Intervention:   Other: Walnuts
Sponsors:   UConn Health;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Weill Medical College of Cornell University;   University of Connecticut;   The Jackson Laboratory for Genomic Medicine;   California Walnut Commission;   Spanish National Research Council
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Condition:   Glioma
Interventions:   Drug: Pembrolizumab;   Combination Product: Olaparib and Temozolomide
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
RFA Treatment for Papillary Thyroid Microcarcinoma
Condition:   Papillary Thyroid Microcarcinoma
Intervention:   Procedure: Radiofrequency Ablation
Sponsor:   Columbia University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 14, 2022 / by / in
Radiofrequency Ablation for BIII Thyroid Nodules
Condition:   Indeterminate Bethesda III Thyroid Nodules
Intervention:   Procedure: Radiofrequency Ablation
Sponsor:   Columbia University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 14, 2022 / by / in